Literature DB >> 7852108

Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning.

E B Hug1, M M Fitzek, N J Liebsch, J E Munzenrider.   

Abstract

PURPOSE: Tumors of the axial skeleton are at high risk for local failure. Total surgical resection is rarely possible. Critical normal tissues limit the efficacy of conventional photon therapy. This study reviews our experience of using combined high dose proton and photon radiation therapy following three-dimensional (3D) treatment planning. METHODS AND MATERIALS: Between December 1980 and September 1992, 47 patients were treated at the Massachusetts General Hospital and Harvard Cyclotron Laboratory for primary or recurrent chordomas and chondrosarcomas (group 1, 20 patients), osteogenic sarcomas (group 2, 15 patients) and giant cell tumors, osteo-or chondroblastomas (group 3, 12 patients). Radiation treatment was given postoperatively in 23 patients, pre- and postoperatively in 17 patients, and 7 patients received radiation therapy as definitive treatment modality following biopsy only. The proton radiation component was delivered using a 160 MeV proton beam and the photon component using megavoltage photons up to 23 MV energy with 1.8-2.0 Cobalt Gray Equivalent (CGE) per fraction, once a day. Total external beam target dose ranged from 55.3 CGE to 82.0 CGE with mean target doses of 73.9 CGE (group 1), 69.8 CGE (group 2), and 61.8 CGE (group 3).
RESULTS: Group 1 (chordoma and chondrosarcoma): Five of 14 patients (36%) with chordoma recurred locally, and 2 out of 5 patients developed distant metastasis, resulting in 1 death from disease. A trend for improved local control was noted for primary vs. recurrent tumors, target doses > 77 CGE and gross total resection. All patients with chondrosarcoma achieved and maintained local control and disease-free status. Five-year actuarial local control and overall survival rates were 53% and 50% for chordomas and 100% and 100% for chondrosarcomas, respectively. Group 2 (osteogenic sarcoma): Three of 15 patients (20%) never achieved local control and died within 6 months of completion of radiation treatment. Only 1 out of 12 patients who were controlled for more than 6 months failed locally, yielding a 5-year local control rate of 59% for 15 patients. Overall, 4 patients (27%) developed distant metastasis (two in patients with uncontrolled primary); 4 patients succumbed to their disease, 3 patients died of intercurrent disease, resulting in overall survival of 44% at 5 years. Group 3 (giant cell tumors, osteo- and chondroblastoma): One of 8 patients with giant cell tumor failed locally, 1 patient distantly, and all patients are alive. Three of 4 patients with osteo- or chondroblastoma are alive and well. One patient suffered local recurrence and died of disease. Local control rate and overall survival for this group of 12 patients was 76% and 87% and local control for patients with giant cell tumors 83% at 5 years. In the majority of cases radiotherapy was well tolerated. However, one patient with a large base of skull tumor developed retinopathy, one patient required enucleation of a previously blind eye, and another patient with sacral tumor developed chronic diarrhea.
CONCLUSION: Combined proton and photon radiation therapy optimized by 3D treatment planning, allows the delivery of higher radiation doses to tumors of the axial skeleton, while respecting normal tissue constraints. High radiation doses can result in improved long-term local control.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852108     DOI: 10.1016/0360-3016(94)00390-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  Giant-cell tumors of the sphenoid bone in four children: radiological, clinical, and pathological findings.

Authors:  A L Weber; E B Hug; M W Muenter; H D Curtin
Journal:  Skull Base Surg       Date:  1997

Review 3.  Radiation techniques in neuro-oncology.

Authors:  Deepak Khuntia; Wolfgang A Tomé; Minesh P Mehta
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  The determination of a dose deposited in reference medium due to (p,n) reaction occurring during proton therapy.

Authors:  Anna Dawidowska; Monika Paluch Ferszt; Adam Konefał
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-05

5.  Proton radiation therapy for pediatric malignancies: status report.

Authors:  E B Hug; J D Slater
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

6.  Carbon ion radiotherapy for sacral chordoma.

Authors:  R Imai; T Kamada; S Sugahara; H Tsuji; H Tsujii
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 7.  Tumors of the osseous spine.

Authors:  Narayan Sundaresan; Stephano Boriani; Allen Rothman; Robert Holtzman
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

8.  Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.

Authors:  Thomas F DeLaney; Norbert J Liebsch; Francis X Pedlow; Judith Adams; Susan Dean; Beow Y Yeap; Patricia McManus; Andrew E Rosenberg; G Petur Nielsen; David C Harmon; Ira J Spiro; Kevin A Raskin; Herman D Suit; Sam S Yoon; Francis J Hornicek
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-25       Impact factor: 7.038

9.  [Surgery of primary malignant bone tumors].

Authors:  S Flege; M Kuhlen; M Paulussen; S Bielack; H Jürgens
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

10.  Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control?

Authors:  Tomohiro Fujiwara; Yusuke Tsuda; Jonathan Stevenson; Michael Parry; Lee Jeys
Journal:  Int Orthop       Date:  2019-12-20       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.